Zaid Al-Wahab, MD
Gynecologic Oncology · Grosse Pointe, MINPI 1932300290
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,323 of the $8,578 with a category attached, or 85.4%. AstraZeneca accounts for 87.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $3,088 and has fallen 79.9% since, to $620 in 2025.
Across 35 payments — averaging $245.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Merck$253
- Caris MPI, Inc.$168
- Regeneron Healthcare Solutions, Inc.$130
- AbbVie$125
- GSK$114
- plus $316 from 10 others
What the payments were for
- Consulting fees$7,32385%
- Food & beverage$1,25415%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $7,471 |
| Merck | 6 | $253 |
| Caris MPI, Inc. | 1 | $168 |
| Regeneron Healthcare Solutions, Inc. | 1 | $130 |
| AbbVie | 1 | $125 |
| GSK | 6 | $114 |
| Davol Inc. | 3 | $74 |
| BD | 2 | $54 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Eisai Inc. | 2 | $51 |
| Tempus AI, Inc | 1 | $26 |
| Smith+Nephew | 1 | $15 |
| LSI Solutions Inc | 1 | $15 |
| Intuitive Surgical | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$4,688
- MI CANCER SEEK$168
- LIBTAYO$130
- Elahere$125
How this compares
$8,578 in reported general payments places this provider in the 85th percentile of 43 gynecologic oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 11 | $128 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $75 |
| Ibuprofen | 12 | $48 |
| Oxycodone Hcl | 16 | $31 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Grosse Pointe
- Robert MorrisDetroit$807K
- Ira WinerDetroit$25K
- Morgan TaylorDetroit$23K
- Radhika GogoiDetroit$12K
- Douglas PugmireRochester Hills$9K
- Gregory SuttonSaginaw$8K
- Ahmad AwadaDetroit$5K
- Kevin BraderWyoming$5K
- Mae ZakhourGrand Rapids$5K
- Jill GadzinskiRoyal Oak$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.